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Abstract 
A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of 
Montelukast (MO) in human plasma using Montelukast-d6 (MOD6) as an 
internal standard (IS) is discussed here. Chromatographic separation was 
performed on YMC-pack pro C18, 50 x 4.6 mm, S-3 μm column with an isocratic 
mobile phase composed of 10mM ammonium formate (pH 4.0):acetonitrile 
(20:80 v/v), at a flow-rate of 0.8 mL min
−1. MO and MOD6 were detected with 
proton adducts at m/z 586.2→568.2 and 592.3→574.2 in multiple reaction 
monitoring (MRM) positive mode respectively. MO and MOD6 were extracted 
using acetonitrile as precipitating agent. The method was validated over a linear 
concentration range of 1.0–800.0 ng mL
−1 with correlation coefficient (r
2)  ≥ 
0.9996. The intraday precision and accuracy were within 1.91–7.10 and 98.32–
99.17. The inter-day precision and accuracy were within 3.42–4.41% and 
98.14–99.27% for MO. Both analytes were found to be stable throughout three 
freeze-thawing cycles, bench top, and autosampler stability studies. This 
method was utilized successfully for the analysis of plasma samples following 
oral administration of MO (5 mg) in 31 healthy Indian male human volunteers 
under fasting conditions. 412  B. R. Challa et al.:  
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Introduction 
Montelukast, {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-
methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid, has a molecular formula 









Fig. 1.  Chemical structures of Montelukast (a) and Montelukast-d6 sodium salt (b). 
Montelukast is a leukotriene receptor antagonist (LTRA) used for the treatment of asthma 
and to relieve symptoms of seasonal allergies. MO is usually administered orally. Mo is a 
CysLT1 antagonist; it blocks the action of leukotriene D4 on the cysteinyl leukotriene 
receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the 
bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. 
MO is more than 99% bound to plasma proteins with bioavailability of 63% to 73% and half 
life of 2.7–5.5 h and extensively metabolized by liver and excreted by biliary [1]. 
Several methods were developed for quantitative estimation of MO such as voltametric 
[10], capillary electrophoresis [12], spectroflurometry [15] spectrophotometry [17], and 
liquid chromatography (LC) [2–9,  11,  13,  14,  16]. Some methods were developed in 
pharmaceutical [11–14, 16, 17] and biological fluids [2–10, 15]. Moreover, voltametric [10], 
capillary electrophoresis [12], spectrophotometry [17], spectroflurometry [15] involves 
tedious procedure and too many steps which do not satisfy the determination of the 
samples. Quantification of MO in human plasma using HPLC was developed by few 
authors [3–8], which involves longer run time and are more expensive. Quantification of 
MO in human plasma using LC-MS/MS was developed by Bharathi D.V. et al. (2009) [2], 
where they observed a good linearity between the concentration ranges of 0.25–800.0 ng 
mL
−1. However, the samples were pretreated with liquid–liquid extraction (LLE) and 
amlodipine was used as internal standard. 
The proposed method involves high sensitivity, selectivity, and is reproducible for 
quantification of MO in plasma samples using samples acetonitrile precipitating agent by 
LC-ESI-MS/MS. Deuterated internal standard MOD6 (Fig. 1b) was used. We have devel-
oped and validated the method over a concentration range of 1.0–800.0 ng mL
−1 using 
200µL plasma samples. Limit of detection (LOD) was proved for 0.02 pg mL
−1. Elution time 
was achieved in 2.8 min for both MO and MOD6. This method was developed and 
validated as per FDA guidelines and was successfully employed in the analysis of plasma 
samples following oral administration of MO (5 mg) in healthy human volunteers [18]. 
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Material and methods 
Standards and chemicals 
MO was obtained from Varda Biotech Pvt. Ltd, Mumbai, India. MOD6 was obtained from 
TRC (Torrent research chemicals, Ontario) Canada. Acetonitrile, ammonium formate, 
formic acid were purchased from SD Fine Chemicals Ltd, Mumbai, India. Millipore water 
was used for all the experiments. 
Instrumentation  
HPLC system (1200 series model, Agilent Technologies, Waldbronn, Germany), Mass 
spectrometry API 4000 triple quadrupole instrument (ABI-SCIEX, Toronto, Canada) using 
MRM.  
Detection 
Turbo ionspray positive mode with unit resolution MRM was used for the detection. [M-H]
+ 
(m/z 586.3) was monitored as the precursor ion for MO and fragmented at m/z: 568.2 was 
chosen as product ion. For internal standard, the [M-H]
+ (m/z: 592.3) was monitored as the 
precursor ion and a fragmented at m/z 574.3 was monitored as the product ion. Mass 
parameters were optimized as source temperature 550°C, nebulizer gas 25 psi, heater gas 
30 psi, curtain gas 20 psi, CAD gas 4 psi (nitrogen), ion spray voltage 5500 volts, source 
flow rate 800 µL min
−1 without split, entrance potential 10V, declustering potential 65V for 
MO and 65V for MOD6, collision energy 25 V for both MO and MOD6, collision cell exit 
potential 8V for both MO and MOD6. 
Chromatographic conditions 
YMC-pack pro C18, 50 x 4.6 mm, S-3 μm was selected as the analytical column. The 
mobile phase composition was 10mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v). 
Flow rate of the mobile phase was set at 0.8 mL min
−1 and 10 μL injection volume was 
used. Column temperature was set at 45°C. MOD6 was found to be appropriate internal 
standard. Retention time of MO and MOD6 were found to be 2.8 ± 0.2 min, with overall 
runtime of 5 min. 
Preparation of standards and quality control (QC) Samples 
Standard stock solutions of MO (100 µg mL
−1) and MOD6 (100 µg mL
−1) were prepared in 
methanol. MOD6 standard solutions (400 ng mL
−1) were prepared in 50% methanol from 
MOD6 standard stock solution. Standard stock solutions of MO were added to drug-free 
human plasma to obtain MO concentration levels of 1.00, 2.00, 5.00, 10.00, 50.00, 100.00, 
200.00, 400.00, 600.00, and 800.00 ng mL
−1 for analytical standards and 1.00, 3.00, 
240.00, and 560.00 for quality control standards and stored in a −30°C set point freezer 
until analysis. Standard stock solutions and IS Standard solutions were stored in 
refrigerator conditions 2–8°C until analysis. Aqueous standard solutions were prepared in 
a mixture of 10mM ammonium formate pH 4.0:acetonitrile(1:9 v/v) and stored in 
refrigerator conditions 2–8°C until analysis. 
Sample preparation 
50 µL of MOD6 standard solution (400 ng mL
−1) was added into labeled microcentrifuged 
tubes and spiked 200 µL of plasma sample (respective concentration) into each tube and 
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vortexed briefly. Plasma samples were cleaned with 750 µL of precipitating agent 
acetonitrile and vortexed briefly for about 5 min. Then the samples were centrifuged at 
14000 g.force for approximately 10 min at ambient temperature. The supernatant from 
each sample was transferred into pre-labeled auto sampler vials for injection. Extraction 
was carried out under the absence of white light. 
Recovery 
The extraction recoveries of MO and MOD6 from human plasma were determined by 
analyzing quality control samples. Recoveries at three concentrations (3.00, 240.00, and 
560.00 ng mL
−1) were determined by comparing peak areas obtained from the plasma 
sample and the standard solution spiked with the blank plasma residue.  
Selectivity  
The response (peak area) was determined in blank plasma samples (six replicates from 
different plasma) and spiked LOQ was prepared from the same plasma. The peak area of 
blank samples should not be more than 20% of the mean peak area of LOQ of MO and not 
more than 5% of MOD6. The precision and mean accuracy of LOQ concentrations must 
be ≤ 20 and ± 20 % respectively. The signal to noise (S/N) for LOQ was found to be ≥ 5. 
Analytical curves 
The analytical curves were constructed using values ranging from 1.00 to 800.00 ng mL
−1 
of MO in human plasma. Calibration curves were obtained by weighted 1 quadratic model 
with log transformed regression analysis (y = ax
2 + bx + c). (x=MO concentration in plasma 
sample, y=Area ratio of MO and MOD6)The ratio of MO peak area to MOD6 peak area 
was plotted against the ratio of MO concentration to that of MOD6 concentration in 
ng mL
−1.Calibration curve standard samples and quality control samples were prepared in 
replicates (n=6) for analysis. Accuracy and precision for the back calculated 
concentrations of the calibration points should be within ≤ 15 and ± 15% of their nominal 
values. However, for LLOQ, the precision and accuracy should be within ≤ 20 and ± 20%. 
Stability (freeze–thaw, auto sampler, bench top, long term)  
Low quality control and high quality control samples (n=6) were retrieved from deep 
freezer after three freeze–thaw cycles according to the clinical protocols. Samples were 
frozen at −30°C in three cycles of 24, 36, and 48 h. In addition, the long-term stability of 
MO in quality control samples was also evaluated by analysis after 55 days of storage at 
−30°C. Autosampler stability was studied following 76 h-storage period in the autosampler 
tray. Bench top stability was studied for 27-h period. Stability samples were processed and 
extracted along with the freshly spiked calibration curve standards. The precision and 
accuracy for the stability samples must be within ≤ 15 and ± 15%, respectively, of their 
nominal concentrations. 
Analysis of patient samples 
The bioanalytical method described above was used to determine MO concentrations in 
plasma following oral administration of healthy human volunteers. Each volunteer obtained 
written informed consent before participating in this study. Thirty-one healthy volunteers 
were chosen as subjects and administered 5  mg dose (one 5  mg tablet) by oral 
administration with 240 mL of drinking water. The reference product, Singulair tablets 
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(Merck&CO) 5 mg and test product, MO tablets (test tablet) 5 mg were used. Study 
protocol was approved by IEC (Institutional Ethical committee) as per ICMR (Indian council 
of medical research) and the research followed the ethical standard formulated in the 
Helsinki declaration of 1964, revised in 2000. Blood samples were collected as pre-dose 
(0) h, 5 min prior to dosing followed by further samples at 0.5, 1.0, 1.333, 1.667, 2.0, 
2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 13.0, 16.0, 20.0, and 24 h. 
After dosing, 5 mL blood was collected each time in vaccutainers containing K2EDTA. A 
total of 42 (21 time points for test and 21 time points for reference) time points were 
collected from each volunteer. The samples were centrifuged at 3200 rpm, 10°C, 10 min, 
and stored at −30°C until sample analysis. Test and reference were administered to same 
human volunteers under fasting conditions separately with proper washing periods 
(40 days gap between test and reference doses) as per protocol approved by IEC. 
Pharmacokinetics and statistical analysis 
Pharmacokinetics parameters from the human plasma samples were calculated by a 
noncompartmental statistics model using WinNon-Lin5.0 software (Pharsight, USA). Blood 
samples were taken for a period of 3 to 5 times the terminal elimination half-life (t1/2) and it 
was considered as the area under the concentration time curve (AUC) ratio higher than 
80% as per FDA guidelines [19, 20]. Plasma MO concentration-time profiles were visually 
inspected and Cmax  and Tmax values were determined. The AUC0–t was obtained by 
trapezoidal method. AUC0–∞ was calculated up to the last measureable concentration and 
extrapolations were obtained using the last measureable concentration and the terminal 
elimination rate constant (Ke). The terminal elimination rate constant (Ke), was estimated 
from the slope of the terminal exponential phase of the plasma of MO concentration–time 
curve by means of the linear regression method. The terminal elimination half-life, t1/2, was 
then calculated as 0.693/Ke. Regarding AUC0–t and Cmax bioequivalence was assessed by 
means of analysis of variance (ANOVA) and calculating the standard 90% confidence 
intervals (90% CIs) of the ratios test/reference (logarithmically transformed data). The 
bioequivalence was considered when the ratio of averages of log-transformed data was 
within 80–125% for AUC0–t and Cmax. 
Results and Discussion 
Method development and validation 
LC-MS/MS has been used as one of the most powerful analytical tool in clinical 
pharmacokinetics for its selectivity, sensitivity, and reproducibility. The aim of the present 
study is to develop and validate a simple, sensitive, and rapid assay method for the 
quantitative determination of MO from plasma samples. A simple protein precipitation was 
used for extraction of MO and MOD6 from the plasma samples. Chromatographic 
conditions, especially the composition and nature of the mobile phase, were optimized 
through several trials to achieve the best resolution and increase the signal of MO and 
MOD6. The MS optimization was performed by direct infusion of solutions of both MO and 
MOD6 into the ESI source of the mass spectrometer. The critical parameters in the ESI 
source included the needle (ESI) voltage, which was directly related to the charged droplet 
formation and to the amount of gaseous ions formed. Capillary voltage was related to the 
gaseous ion guidance to the inside of the MS and was the last barrier between the 
atmospheric pressure and the high vacuum of the mass spectrometer. Other parameters, 
such as the nebulizer and the desolvation gases were optimized to obtain a better spray 
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shape, resulting in better ionization and droplet drying to form, in our case, the protonated 
ionic MO and MOD6 molecules (Fig. 1). A CAD product ion spectrum for MO and MOD6 
yielded high-abundance fragment ions of m/z 568.2 and m/z 574.2 respectively (Fig. 2). 
After the MRM channels were tuned, the mobile phase was changed from an aqueous 
phase to a more organic phase with acid dopant. A good separation and elution were 
achieved using 10 mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v) as the mobile 
phase, at a flow-rate of 0.8 mL min
−1 and injection volume of 10 µL. 
 
Fig. 2.   CAD mass spectra of MO Q1/Q3, MOD6 Q1/Q3. 
Selectivity 
The analysis of MO and MOD6 using MRM function was highly selective with no interfering 
compounds (Fig. 3a)(selectivity was performed by using six different plasma lots, here 
showing only one blank plasma). MRM Chromatograms obtained from plasma spiked with 
MO (1.0 ng mL
−1) and MOD6 (400 ng mL
−1) are shown in Fig. 3b. LOQ S/N was found >5. 
Matrix effect 
Matrix effect was determined by comparing peak area ratio obtained from the standard 
solution spiked with blank plasma before extraction and after extraction, and the precision 
for matrix effect at low, medium, and high concentrations must be less than 15%. The 
precision for the Montelukast matrix effect at all concentrations were determined to be less 
than 15%. 
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Fig. 3a.   MRM chromatogram of MO and 
MOD6 in human blank plasma. 
Fig. 3b.   MRM chromatogram of MO and 
MOD6 in human plasma spiked 
with MO (1.00ng/ml), and MOD6 
(400.00 ng/ml)[LOQ]. 
Linearity, precision, and accuracy of calibration standards 
Calibration curves were plotted as the peak area ratio (MO/MOD6) versus (MO/MOD6) 
concentration. Calibration was found to be linear over the concentration range of 1.00–
800.00 ng mL
−1. The RSD’s were less than 5% and the accuracy ranged from 96.82 to 
102.43%. The determination coefficients (r
2) were greater than 0.9996 for all curves 
(Tab. 1). These results indicate the adequate reliability and reproducibility of this method 
within the analytical range 
Precision and accuracy of quality control standards 
Precision and accuracy for this method was controlled by calculating the intra and inter-
batch variations at three concentrations (3.00, 240.00, and 560.00 ng mL
−1) of QC 
samples in six replicates. As shown in Table 2, the intra-batch RSD’s were less than 
7.10%.The intra and inter-day precision was within 1.91 to 7.10 and 3.41 to 4.40% and the 
intra and inter-day accuracy within 98.32 to 99.35% and 98.12 to 99.24% for MO (Table 2). 
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(n = 6) 
Accuracy 
% 
  1.00    1.00  ±  0.03  3.0  100.00 
  2.00    2.02  ±  0.08  4.0  101.00 
  5.00    5.05  ±  0.07  1.4  101.00 
 10.00    9.86  ±  0.18  1.8   98.63 
 50.00   48.42  ±  2.43  5.0   96.82 
100.00  102.40 ± 4.22  4.1  102.43 
200.00  204.07 ± 3.18  1.6  102.00 
400.00  400.76 ± 8.46  2.1  100.21 
600.00  605.05 ± 7.69  1.3  100.85 
800.00  780.18 ± 7.71  1.0    97.52 
a 
100  
measured   ion concentrat   Mean
deviation   Standard
    RSD ⋅ =  
 
Tab. 2.  Precision and accuracy (analysis with spiked plasma samples at three different 
concentrations) 

























3.00    2.95  ± 0.21  7.10  98.32    2.95  ±   0.13  4.40  98.31 
240.00 238.31  ±  4.60  1.91  99.35  238.13 ±   8.21  3.41  99.24 
560.00 552.79  ±32.12  5.84  98.70  549.51 ± 20.79  3.81  98.12 
a 
100  
measured   ion concentrat   Mean
deviation   Standard
    RSD ⋅ =  
 
Recovery 
The recovery following the sample preparation using precipitation method with acetonitrile 
was calculated by comparing the peak area ratios of MO in plasma samples with the peak 
area ratios of solvent samples and was estimated at control levels of MO. The recovery of 
MO determined at three different concentrations 3.00, 240.00, and 560.00 ng mL
−1 was 
found to be 76.05, 69.67, and 57.33% respectively. The overall average recovery of MO 
and MOD6 were found to be 67.68 and 64.87%, respectively. 
Limit of Detection (LOD) 
The limit of detection was determined using aqueous standard solution. For Montelukast, 
10 μL of a 20.00 pg mL
−1 aqueous standard solution was injected and proved 0.20 pg limit 
of detection(LOD) for the instrument. 
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Room temperature stability for 27 h in plasma 
  3.00    2.91  ±  0.08  2.79   97.00 
560.00  543.00 ± 8.76  1.61    96.96 
Auto sampler stability for 76 h 
  3.00    2.91  ±    0.06 2.08    97.00 
560.00  564.33 ± 13.71 2.43  100.77 
Long-term stability for 55 days at −30°C 
  3.00    2.98  ±    0.14 4.60    99.33 
560.00  544.83 ± 11.02 2.02    97.29 
Freeze and thaw stability at 48 h 
  3.00    2.93  ±    0.08 2.69    97.67 
560.00 541.83±  12.38  2.29    96.76 
a 
100  
measured   ion concentrat   Mean
deviation   Standard
    RSD ⋅ =  
Stability (freeze-thaw, auto sampler, bench top, long term) 
Quantification of MO in plasma subjected to three freeze-thaw (−30°C to room 
temperature) cycles showed the stability of the analyte. No significant degradation of the 
MO was observed even after 76-h storage period in the auto sampler tray and the final 
concentrations of MO was between 97.0 to 100.8% of the theoretical values. In addition, 
the long-term stability of MO in QC samples after 55 days of storage at −30°C was also 
evaluated. The concentrations ranged from 99.3 to 97.3% of the theoretical values. These 
results confirmed the stability of MO in human plasma for at least 55 days at −30°C. 
(Tab. 3). 
 
Fig. 4.   Mean plasma concentrations of test vs. reference after a 5 mg single oral dose 
(one 5 mg tablet) in 31 healthy volunteers. 
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Application to biological samples 
The above-validated method was used in the determination of MO in plasma samples for 
establishing the bioequivalence of a single 5-mg dose (one 5 mg tablet) in 31 healthy 
human volunteers. Typical plasma concentration versus time profiles was shown in Fig. 4. 
All the plasma concentrations  of MO were in the standard curve region and remained 
above the 1.00 ng mL
−1 LOQ for the entire sampling period. The Pharmacokinetic 
parameters and 90%CI were shown in Table 4, 5. Therefore, it can be concluded that the 
two Montelukast formulations (reference and test) analyzed were bioequivalent according 
to regulatory requirements [19, 20] (Fig.4) 
Tab. 4.   Mean pharmacokinetic parameters of Montelukast in 31 healthy human 
volunteers after oral administration of 5 mg of test and reference products 
Reference Test  Pharmacokinetic  
parameter  Mean±SD CV% Mean±SD CV% 
Cmax (ng mL
−1)    338.23 ± 126.44 37.38   369.29 ± 137.35  37.19 
AUC0–t (ng.hr/ml)  2416.53 ±   66.29  2.74 2417.26  ±   63.58   2.63 
AUC0–∞ (ng.hr/ml)  2486.54 ±   72.15  2.90 2490.26  ±   71.43   2.87 
tmax  (hr)  2.67 – 2.67 – 
t1/2  4.54 – 4.99 – 
AUC0–∞ … Area under the curve extrapolated to infinity; 
AUC0–t … Area under the curve up to the last sampling time; 
Cmax … The maximum plasma concentration 
Tmax … The time to reach peak concentration 
 
Tab. 5.   90% Confidence intervals for log-transformed pharmacokinetic parameters of 
Montelukast after administration of 5 mg of test and reference products in 31 
healthy human volunteers 
Pharmacokinetic parameter Cmax (T/R) AUC0–t (T/R) AUC0–∞ (T/R) 
90% CI  109.19  100.03  100.15 
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